|Title||Higher Sensitivity of the recomLine Borrelia IgG Immunoblot Kit than of the Standard Lyme IgG Immunoblot Kit According to CDC Testing Criteria|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Kadkhoda K, Gretchen A|
|Journal||J Clin Microbiol.|
Lyme disease (LD), caused by Borrelia burgdorferi sensu lato, is the most common tick-borne disease in the United States and Canada. Left untreated, LD may progress through three stages: an early localized stage (hallmarked by an erythema migrans [EM] rash), the early disseminated stage, and the late stage (1). Serodiagnosis offers suboptimal sensitivity during the first stage. The recommended two-tiered testing algorithm by the U.S. Centers for Disease Control and Prevention (CDC) requires screening by an enzyme-linked immunosorbent assay (ELISA), and if the results are positive/equivocal, at least 5 out of 10 diagnostic bands (p18, OspC, p28, p30, p39, p41, p45, p58, p66, and p93) must be present on an IgG immunoblot for a confirmed positive result (2).